Insulin-like growth factor-I (rhIGF-I) therapy of short stature

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 4, 2008, Pages 301-315

  Rosenbloom, Arlan L ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Children's Medical Center of North Florida   (United States)

Author keywords

Acid labile subunit (ALS); GH receptor deficiency (GHRD); Growth; Growth hormone (GH); Idiopathic short stature; IGF I binding protein 3 (IGFBP 3); Insulin like growth factor I (IGF I); Mecasermin; Mecasermin rinfabate

Indexed keywords

ELECTROLYTE; GLUCOSE; GONADORELIN DERIVATIVE; GROWTH HORMONE; GROWTH HORMONE ANTIBODY; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; INSULIN; PLACEBO; RECOMBINANT GROWTH FACTOR; RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ASYSTOLE; BODY FAT; BODY MASS; BRAIN PSEUDOTUMOR; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CARDIOVASCULAR DISEASE; CHILD GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; FACIAL NERVE PARALYSIS; FACIES; GENE MUTATION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HAIR LOSS; HORMONE BINDING; HORMONE RESISTANCE; HORMONE SUBSTITUTION; HUMAN; HYPOACUSIS; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IDIOPATHIC DISEASE; INJECTION SITE PAIN; LIPOHYPERTROPHY; LONG TERM CARE; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOID HYPERPLASIA; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PAPILLEDEMA; PAROTITIS; PROTEIN SYNTHESIS; RARE DISEASE; REVIEW; SEIZURE; SHORT COURSE THERAPY; SHORT STATURE; SIDE EFFECT; SNORING; TACHYCARDIA; THYMUS DISEASE; TONSIL DISEASE; VOMITING;

EID: 44949123826     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.4.301     Document Type: Review

References (72)

1. Rosenbloom AL. Is there a role for recombinant insulin-like growth factor-I (rhIGF-I) in the treatment of idiopathic short stature? Lancet 2006; 368: 612-616.
2. Rosenbloom AL. Recombinant human insulin-like growth factor-I (rhIGF-I) and rhIGF-I/rhIGF-I-binding-protein-3: new growth treatment options? J Pediatr 2007; 150: 7-11.
3. Daughaday WH. Endocrinology - the way we were: a personal history of somatomedin. Growth Horn IGF Res 2006; 16: S3-S5.
4. van der Eerden, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev 2003; 24: 782-801.
5. Domene HM, Bengolea SV, Jasper HG, Boisclair YR. Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest 2005; 28(Suppl): 43-46.
6. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Pollock BH. Growth in growth hormone insensitivity. Trends Endocrinol Metab 1994; 5: 296-303.
7. Rosenbloom AL, Guevara-Aguirre J. Controversy in clinical endocrinology: reclassification of IGF-1 production and action disorders. J Clin Endocrinol Metab 2006; 91: 4232-4234.
8. Walenkamp MJ, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ, de Laat JA, Breuning MB, Romijn JA, Wit JM. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005; 90: 2855-2864.
9. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects and half-lives of intravenously administered insulin-like growth factor I in healthy adults. N Engl J Med 1987; 317: 137-140.
10. Turkal JI, Keller U, Ninnis R, Vosmeer S, Stauffacher W. Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 1992; 75: 1186-1191.
11. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. Am J Physiol 1992; 262: E130-E133.
12. Usala A-L, Madigan T, Burguera B, Sinha MK, Caro JF, Cunningham P, Powell JG, Butler PC. Brief report: Treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes. N Engl J Med 1992; 327: 853-857.
13. Rosenbloom AL, Ongley JP. Serum calcium phosphorus and magnesium decrement during oral glucose tolerance testing: alteration in pre-clinical and overt diabetes mellitus in childhood. In: Catin M, Selig M, eds. Magnesium in Health and Disease. Jamaica, NY: Spectrum Publishers Inc, 1980; 297-304.
14. Guler H-P, Schmid C, Zapp J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989; 86: 2868-2872.
15. Takano K, Hizuka N, Shizume K, Asakawa K, Fukuda I, Demura H. Repeated sc administration of recombinant human insulin-like growth factor I (IGF-I) to human subjects for 7 days. Growth Regul 1991; 1: 23-28.
16. Laron Z, Erster B, Klinger B, Anin S. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988; ii: 1170-1172.
17. Laron Z, Klinger B, Silbergeld A, Lewin R, Erster B, Gil-Ad I. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH. Acta Endocrinol 1990; 123: 378-382.
18. Klinger B, Garty M, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Div Pharmacol Ther 1990; 15: 196-199.
19. Laron Z, Klinger B, Jensen LT, Erster B. Biochemical and hormonal changes induced by one week of administration of rIGF-I to patients with Laron type dwarfism. Clin Endocrinol 1991; 35: 145-160.
20. Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska JB, Underwood LE. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). N Engl J Med 1991; 324: 1483-1488.
21. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993; 77: 273-280.
22. Lee PDK, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Aguirre J. Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. J Clin Endocrinol Metab 1997; 82: 2266-2274.
23. Heinrichs C, Vis HL, Bergmann P, Wilton P, Bourguignon JP. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin Endocrinol 1993; 38: 647-651.
24. Martinez V, Vasconez O, Martinez AL, Moreno Z, Davila N, Rosenbloom AL, Diamond FB, Bachrach L, Rosenfeld RG, Guevara-Aguirre J. Body changes in adolescent patients with growth hormone receptor deficiency receiving recombinant human insulin-like growth factor I and luteinizing hormone-releasing hormone analogue: preliminary results. Acta Paediatr 1994; Suppl 399: 133-136.
25. Wilson KF, Fielder PJ, Guevara-Aguirre J, Cohen P, Vasconez O, Martinez V, Martinez A, Rosenbloom AL, Rosenfeld RG. Long-term effects of insulin-like growth factor (IGF)-I treatment on serum IGFs and IGF binding proteins in adolescent patients with growth hormone receptor deficiency. Clin Endocrinol 1995; 42: 399-407.
26. Vasconez O, Martinez V, Martinez AL, Hidalgo F, Diamond FB, Rosenbloom AL, Rosenfeld RG, Guevara-Aguirre J. Heart rate increases in patients with growth hormone receptor deficiency treated with insulin-like growth factor I. Acta Paediatr 1994; Suppl 399: 137-139.
27. Duerr RL, McKirnan MD, Gim RD, Clark RG, Chien KR, Ross J Jr. Cardiovascular effects of insulin-like growth factor-I and growth hormone in chronic left ventricular failure in the rat. Circulation 1996; 93: 2188-2196.
28. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. Clin Invest 1995; 95: 619-627.
29. Crosnier H, Gourmelen M, Prëvot C, Rappaport R. Effects of nutrient intake on growth, insulin-like growth factors, and their binding proteins in a Laron-type dwarf. J Clin Endocrinol Metab 1993; 6: 248-250.
30. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG. A randomized double-blind, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-1398.
31. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Rosenfeld RG. Two year treatment of growth hormone receptor deficiency (GHRD) with recombinant insulin-like growth factor-I in 22 children: comparison of two dosage levels and to GH treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
32. Daughaday WH, Rotwein P. Insulin-like growth factors I and II: peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989; 10: 68-91.
33. Klinger B, Laron Z. Three year IGF-I treatment of children with Laron syndrome. J Pediatr Endocrinol Metab, 1995; 8: 149-158.
34. Laron Z, Klinger B, Eshet R, Kaneti H, Karasik A, Silbergeld A. Laron syndrome due to a post-receptor defect: response to IGF-I treatment. Isr J Med Sci 1993; 29: 757-763.
35. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-134.
36. Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hübner C. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2006; 2: 395-407.
37. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE; GH Insensitivity Syndrome Collaborative Group. Long-term treatment with recombinant IGF-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrin Metab 2007; 92: 902-910.
38. Camacho-Hubner C, Underwood LE, Yordam N, Yuksel B, Smith AV, Attie KM, Savage MO. Once daily rhIGF-I/rhIGFBP-3 treatment improves growth velocity in children with severe primary IGF-I deficiency: results of a multicenter clinical trial. 88th Annual Meeting of The Endocrine Society, Boston, MA, 2006; Abst OR 40-1.
39. Camacho-Hübner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol A, Allan G, Sommer A, Savage MO. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006; 91: 1246-1253.
40. Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987; 8: 426-438.
41. Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, Ohlsson C. Liver-derived insulin-like growth factor-I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96: 7088-7092.
42. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor-I. Proc Natl Acad Sci USA 1999; 96: 7324-7329.
43. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG. Total absence of functional acid labile subunit, resulting in severe insulin like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006; 91: 1826-1831.
44. Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350: 570-577.
45. Domené HM, Scaglia P, Lteif A, Mahmud FH, Kirmani S, Frystyk J, Bedecarras P, Gutierrez M, Jasper HG. Phenotypic effects of null and haploinsufficiency of acid-labile subunit in a family with two novel IGFALS gene mutations. J Endocrinol Metab 2007; 92: 4444-4450.
46. Guevara-Aguirre J, Guevara-Aguirre M, Rosenbloom AL. Absence of hypoglycemia in response to varying doses of recombinant human insulin-like growth factor-I (rhIGF-I) in children and adolescents with low serum concentrations of IGF-I. Acta Pædiatr 2006; 95: 199-200.
47. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Long-term IGF-I treatment of children with Laron syndrome increases adiposity. Growth Horm IGF Res 2006; 16: 61-64.
48. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
49. Perry JK, Emerald BS, Mertani HC, Lovie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res 2006; 16: 277-289.
50. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease management. J Clin Endocrinol Metab 2004; 89: 2271-2274.
51. Guevara-Aguirre J, Frane J, Bright G. A comparison of four IGF-I assay systems for the detection of biochemical IGF-I deficiency. Seventh Joint Meeting of the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrinology Society, Lyon, France, September, 2005; Abst #139275.
52. Khosravi J, Diamandi A, Bodani U, Khaja N, Krishna RG. Pitfalls of immunoassay and sample for IGF-I: comparison of different assay methodologies using various fresh and stored serum samples. Clin Biochem 2005; 38: 659-66.
53. Han JC, Balagopal P, Sweeten S, Darmaun D, Mauras N. Evidence for hypermetabolism in boys with constitutional delay of growth and maturation. J Clin Endocrinol Metab 2006; 91: 2081-2086.
54. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. Poor reproducibility of IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab 2002; 37: 469-472.
55. Rosenfeld RG, Hwa V. New molecular mechanisms of GH resistance. Eur J Endocrinol 2004; 151 (Suppl): S11-S15.
56. Rosenfeld RG. The IGF system: new developments relevant to pediatric practice. Endocr Dev 2005; 9: 1-10.
57. Clark RG. Recombinant insulin-like growth factor-I as a therapy for IGF-I deficiency in renal failure. Pediatr Nephrol 2005; 20: 290-294.
58. Attie KM, Carlsson LMS, Rundle AC, Sherman BM. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature. J Pediatr 1995; 127: 244-250.
59. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, Schwarze CP, Wollmann HA. Relevance of IGF-I, IGFBP-3, and IGFBP-2 measurements during GH treatment of GH-deficient and non-GH-deficient children and adolescents. Horm. Res 2001; 55: 115-124.
60. Park P, Cohen P. Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 2005; 15: S13-532.
61. Bonioli E, Tarò M, La Rosa C, Citana A, Bertorelli R, Morcaldi G, Gastaldi R, Coviello DA. Heterozygous mutations of growth hormone receptor gene in children with idiopathic short stature. Growth Horm IGF-I Res 2005; 15: 405-410.
62. Hujeirat Y, Hess O, Shalev S, Tenenbaum-Rakover Y. Growth hormone receptor sequence changes do not play a role in determining height in children with idiopathic short stature. Horm Res 2006; 65: 210-216.
63. Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, Saavedra J, Yariz K, Baumbach L, Shuster J. Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature. Growth Horm IGF Res 2007; 17: 261-264.
64. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
65. Clayton PE, Ayoola O, Whatmore AJ. Patient selection for IGF-I therapy. Horm Res 2006; 65 (Suppl 1): 28-34.
66. Lee MM. Idiopathic short stature. N Engl J Med 2006; 354: 2756-2582.
67. Dunkel L. Management of children with idiopathic short stature. Eur J Endocrinol 2006; 155: S35-S38.
68. Fielder PJ, Mortensen DL, Mallet P, Carlsson B, Baxter RC, Clark RG. Differential long-term effects of insulin-like growth factor-I (IGF-I), growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats. Endocrinology 1996; 137: 1913-1920.
69. Tncrelex®. http:/yahoo.brand.edgar-online.com/ fetchFilingFramset.aspx?dcn=0001181431-07-065424&Type=HTML. Accessed 2/5/ 2008.
70. Tercica launches Increlex in the US, long-term treatment of growth failure caused by severe primary IGFD. http://www.medicalnewstoday.com, accessed 2/5/2008.
71. http://clinicaltrials.gov/ct2/show/NCT%2000571727; http:// clinicaltrials.gov/ct2/show/NCT%2000125164; http://clinicaltrials.gov/ ct2/show/NCT00330668; http://clinicaltrials.gov/ct2/show/NCT00125190
72. Collet-Solberg PF, Misra M, on behalf of the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. The role of recombinant human insulin like growth factor 1 in treating children with short stature. J Clin and Endocrinol Metab 2008; 93: 10-18.